Antibodies to watch in 2021

Abstract

In this 12 th annual installment of the Antibodies to Watch article series, we discuss key events in antibody therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency. Of these 16 mAbs, 11 are possible treatments for non-cancer indications and 5 are potential treatments for cancer. Based on the information publicly available as of November 2020, 44 antibody therapeutics are in late-stage clinical studies for non-cancer indications, including 6 for COVID-19, and marketing applications for at least 6 (leronlimab, tezepelumab, faricimab, ligelizumab, garetosmab, and fasinumab) are planned in 2021. In addition, 44 antibody therapeutics are in late-stage clinical studies for cancer indications. Of these 44, marketing application submissions for 13 may be submitted by the end of 2021. *Note added in proof on key events announced during December 1-21, 2020: margetuximab-cmkb and ansuvimab-zykl were approved by FDA on December 16 and 21, 2020, respectively; biologics license applications were submitted for ublituximab and amivantamab.

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study

“…The first ICPi, targeting cytotoxic T lymphocyte–associated antigen 4, earned FDA approval in 2011 [ 8 ]. ICPi blocking programmed cell death protein 1 and programmed death ligand 1 have followed since, and novel agents are currently entering clinical trials [ 9 ].…”

Ensembles in solution as a new paradigm for antibody structure prediction and design

“…1 Three of the top 5 selling drugs in 2019, 2020 and 2021 are in fact antibodies. [2][3][4] This substantial interest has led to a vast amount of experimental data, including affinity and stability measurements as well as structural information.…”

Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions

“…This scientific concept became practical with the advanced engineering technologies to equip antibodies with high specificity to their cognate targets [2,3]. By 2020, more than 90 antibody drugs had been approved by the U.S. Food and Drug Administration (FDA) to treat a series of major diseases, such as autoimmune diseases and cancers [4]. There is no doubt that therapeutic antibodies have achieved significant clinical success and play central roles in revolutionizing many diseases' treatment landscapes.…”